

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/500,838	02/02/2005	Daniel W. Chan	56792(71699)	1171	
21874 EDWARDS A	7590 05/15/2007 NGELL PALMER & DOD	EXAMINER			
P.O. BOX 55874 BOSTON, MA 02205			HARRIS, ALANA M		
			ART UNIT	PAPER NUMBER	
			1643		
•			MAIL DATE	DELIVERY MODE	
			05/15/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.		Applicant(s)	
Office Action Summary		10/500,838		CḤAN ET AL.	
		Examiner		Art Unit	
,		Alana M. Harris,	Ph.D.	1643	
The MAILING DATE	of this communication app	pears on the cove	r sheet with the co	orrespondence ad	ldress
A SHORTENED STATUTC WHICHEVER IS LONGER, - Extensions of time may be available after SIX (6) MONTHS from the mai - If NO period for reply is specified ab - Failure to reply within the set or exte Any reply received by the Office late earned patent term adjustment. See	FROM THE MAILING DA under the provisions of 37 CFR 1.13 ling date of this communication. ove, the maximum statutory period vended period for reply will, by statute or than three months after the mailing	ATE OF THIS CO 36(a). In no event, how will apply and will expire b, cause the application to	OMMUNICATION rever, may a reply be time. SIX (6) MONTHS from to become ABANDONED.	l. ely filed the mailing date of this c O (35 U.S.C. § 133).	
Status	•		. •		
•		action is non-fin	rmal matters, pro		e merits is
Disposition of Claims					
4) ⊠ Claim(s) <u>3-5,9-12,34</u> , 4a) Of the above claim 5) □ Claim(s) is/are 6) □ Claim(s) is/are 7) □ Claim(s) is/are 8) ⊠ Claim(s) <u>See Continu</u>	n(s) is/are withdrave allowed. e rejected. e objected to.	wn from conside	ration.		
Application Papers					· •
9)☐ The specification is ob 10)☐ The drawing(s) filed o Applicant may not requ	n is/are: a) according and according according that any objection to the sheet(s) including the correct	epted or b) ob drawing(s) be held tion is required if th	d in abeyance. See ne drawing(s) is obj	37 CFR 1.85(a). ected to. See 37 C	
Priority under 35 U.S.C. § 119) ·				
2. Certified copies3. Copies of the capplication from	•	is have been rece is have been rece rity documents h u (PCT Rule 17.2	eived. eived in Application ave been receive 2(a)).	on No Id in this National	Stage
Attachment(s) 1) Notice of References Cited (PTC 2) Notice of Draftsperson's Patent 3) Information Disclosure Statement Paper No(s)/Mail Date	Drawing Review (PTO-948)	4) 5) 6)	Paper No(s)/Mail Da	te	

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 3-5,9-12,34,39,40,46,47,62,63,65,70 and 81-84.

Application/Control Number: 10/500,838

Art Unit: 1643

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 3-5, 9-12, 34, 39 and 62, drawn to a method for detection and diagnosis of ovarian cancer comprising at least one protein biomarker.

Group II, claim(s) 40 and 46, drawn to a process for purification of a biomarker comprising fractioning a sample and collecting a fraction that includes one or more biomarkers.

Group III, claim(s) 47, drawn to a kit for aiding the diagnosis of ovarian cancer comprising an adsorbent with one or more biomarkers and a substrate.

Group IV, claim(s) 63, 65 and 70, drawn to a purified protein and a composition comprising said protein.

Group V, claim(s) 81-84, drawn to a method for qualifying ovarian cancer status comprising measuring at least one biomarker selected from the group consisting of transferring, haptoglobulin precursor protein or fragment thereof.

2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature that appears to link Groups I-V is a protein biomarker. U.S. Patent number 5,650,291 (issues July 22, 1997/ IDS reference AC filed September 7, 2004) teaches a tumor-associated antigen (CA 215) protein biomarker with a molecular weight of 60 kd, see column 6, lines 24-31 and column 4, lines 49-53. Therefore, the technical feature

Art Unit: 1643

recited in Groups I-V is not a contribution over the prior art. Accordingly, the groups set forth below are not so linked as to form a single general concept under PCT Rule 13.1.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Page 4

Application/Control Number: 10/500,838

Art Unit: 1643

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571) 272-0831. The Examiner works a flexible schedule, however she can normally be reached between the hours of 7:30 am to 6:30 pm, with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry R. Helms, Ph.D. can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ALANA M. HARRIS, PH.D. PRIMARY EXAMINER

Alana M. Harris, Ph.D.

4 May 2007